Drugs / interleukin-4 PE38KDEL cytotoxin
interleukin-4 PE38KDEL cytotoxin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00014677 | Mar 2001 → Sep 2002 | central nervous system neoplasm | Neurocrine Biosciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 1999-10-14 | Neurocrine Biosciences | Regulatory FDA Approves Fast Track Designation for NBI-3001 in Malignant Brain Tumors gcs-web.com ↗
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the Company's IL-4 Fusion Toxin compound (NBI-3001). |
| 1999-06-29 | Neurocrine Biosciences | Results Nature Medicine Publication Demonstrates IL-4 Fusion Toxin is Effective In Treating Systemic Form of Cancer in Preclinical Models gcs-web.com ↗
The publication reports that in preclinical models of Kaposi's sarcoma (KS), treatment with IL-4 Fusion Toxin resulted in eradication of KS tumors and prevented disease-related symptoms, such as cachexia (weight loss) and lymphophenia. |
| 1998-11-25 | Neurocrine Biosciences | Results Neurocrine Announces Advancement of NBI-3001 for Malignant Brain Tumors: Phase I Results Presented/Initiation of Multi-Center, International Phase I/II Clinical Trial gcs-web.com ↗
The abstract also stated that of nine patients treated, five patients showed evidence of necrosis (tumor cell death) in major sections of tumor by MRI, PET and MR-SPEC scanning. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 1999-10-14 | Neurocrine Biosciences | FDA Approves Fast Track Designation for NBI-3001 in Malignant Brain Tumors gcs-web.com ↗ |
| 1999-06-29 | Neurocrine Biosciences | Nature Medicine Publication Demonstrates IL-4 Fusion Toxin is Effective In Treating Systemic Form of Cancer in Preclinical Models gcs-web.com ↗ |
| 1998-11-25 | Neurocrine Biosciences | Neurocrine Announces Advancement of NBI-3001 for Malignant Brain Tumors: Phase I Results Presented/Initiation of Multi-Center, International Phase I/II Clinical Trial gcs-web.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interleukin-4 PE38KDEL cytotoxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00014677 ↗ |
| Known as | interleukin-4(38-37)-PE38KDEL cytotoxin | “Patients receive interleukin-4(38-37)-PE38KDEL cytotoxin (NBI-3001) intratumorally as a continuous infusion over 4-5 days” NCT00014677 ↗ |
| Known as | NBI-3001 | “Patients receive interleukin-4(38-37)-PE38KDEL cytotoxin (NBI-3001) intratumorally as a continuous infusion over 4-5 days” NCT00014677 ↗ |
| Modality | Protein / enzyme biologic | “interleukin-4(38-37)-PE38KDEL cytotoxin” NCT00014677 ↗ |
| Route | Other | “Patients receive interleukin-4(38-37)-PE38KDEL cytotoxin (NBI-3001) intratumorally as a continuous infusion over 4-5 days” NCT00014677 ↗ |